BioPorto A/S (BIOPOc)
Market Closed
CBOE 
- Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
Want to track BIOPOc and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
BIOPOc is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0133%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XCSE (DKK).
BioPorto A/S (BIOPOc) FAQ
On which exchange is it traded?
BioPorto A/S is listed on CBOE.
What is its stock symbol?
The ticker symbol is BIOPOc.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has BioPorto A/S ever had a stock split?
No, there has never been a stock split.
BioPorto A/S Profile
| Professional Services Industry | Industrials Sector | Mr. Jeffrey N. Haas CEO | CBOE Exchange | DK0011048619 ISIN |
| Denmark Country | 48 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioPorto A/S is a notable entity in the field of in-vitro diagnostics, extensively engaged in the production and supply of biomarker tools and antibodies tailored for clinical research. The company holds a significant presence not only within European borders but also extends its reach across North America, Asia, and other international markets. With its foundation laid in 1917, BioPorto A/S is headquartered in Hellerup, Denmark, symbolizing more than a century of expertise and dedication to advancing medical research and diagnostics through its innovative product offerings.
Products and Services
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) Test: This represents a notable leap in diagnostic assays, being a quantitative particle-enhanced turbidimetric immunoassay. It's specifically engineered to operate seamlessly on automated clinical chemistry analyzers. The test plays a critical role in the early detection of acute kidney injury, providing clinicians with a reliable tool to assess risk and commence timely intervention.
- Monoclonal Antibodies: BioPorto offers a comprehensive range of monoclonal antibodies, designed to meet the stringent requirements of scientific, pharmaceutical, and clinical research. These antibodies are pivotal in the investigation of various diseases, assisting researchers and healthcare professionals in identifying and targeting specific antigens with high precision.
- Enzyme-Linked Immunosorbent Assay (ELISA) Kits: The company's ELISA kits are integral components for the quantitative detection of antigens or antibodies in samples. These kits are utilized extensively in research settings to facilitate the study of numerous biomarkers and infectious diseases, delivering reliable and precise results critical for advancing our understanding of biological processes and disease mechanisms.
- Generic Rapid Assay Device: Catering to the growing needs for quick and effective diagnostic solutions, BioPorto has developed a versatile platform for custom lateral flow assays. This technology enables the development of rapid, point-of-care diagnostic tests, empowering healthcare providers with the ability to deliver swift and accurate diagnostic information, thereby enhancing patient care and management across various medical settings.
Contact Information
Address: Tuborg Havnevej 15, st.
Phone: 45 45 29 00 00
Website: https://bioporto.com
